Investigational drug · Phase 2
EB-DUO-CAR-NK-CEA
Also called: GCC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer Metastatic, Adenocarcinoma of Colon, Colorectal Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EB-DUO-CAR-NK-CEA"
First trial start
2026
Feb 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EB-DUO-CAR-NK-CEA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer Metastatic
- Adenocarcinoma of Colon
- Colorectal Cancer
- Metastatic Colorectal Adenocarcinoma
- Unresectable Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EB-DUO-CAR-NK-CEA" as an intervention, largest first.
Beijing BiotechIndustry
NCT07462650 · 48 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 21, 2027
Drug: EB-DUO-CAR-NK-CEA/GCC (IV) · For: Colorectal Cancer Metastatic; Adenocarcinoma of Colon
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07589517 · 48 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-DUO-CAR-NK-CEA/GCC; Lymphodepletion · For: Colorectal Cancer; Metastatic Colorectal Adenocarcinoma; Unresectable Colorectal Cancer
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
- Phylogenomics, spatiotemporal transcriptional dynamics and Cis-regulatory architecture underlying the Portulaca oleracea antioxidant network under extreme salinity.
da Silva TLC, Ferreira TMM, Barbosa LF, et al. · Plant Sci 2027
- Rubella and congenital rubella syndrome in the GCC countries: A retrospective ecological analysis of elimination progress and scenario-based projections, 2020-2024.
Al Awaidy ST, Mustafa AAM, Al Aamri S, et al. · J Virus Erad 2026
- STRONG3 promotes lignin biosynthesis and culm strength in rice.
Zhao Y, Gao J, Han S, et al. · New Phytol 2026
- CmGT9 represses salt tolerance in grafted melon via CmRAP2.6L coordinating ion and redox homeostasis.
Meng L, Li Y, Liu Y, et al. · Plant Sci 2026
- A visual evoked potential and optical coherence tomography cross-sectional study in patients with Behcet's disease.
Aliyeva G, Şener Ö, Yalçndağ N, et al. · J Neuroimmunol 2026
- SbWRKY62 Coordinates With SbERF096 to Activate Pterostilbene Biosynthesis and Targets a Xylanase Inhibitor Protein for Anthracnose Resistance in Sorghum.
Li Y, Deng B, Gan Y, et al. · Plant Cell Environ 2026
Also in development for Colorectal Cancer Metastatic
- TunlametinibPhase 32 trials
Shanghai Kechow Pharma, Inc. · Colorectal Cancer Metastatic, Melanoma
- HDM2017Phase 22 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · CRC, Colorectal Cancer, Colorectal Cancer Metastatic
- XNW27011ASP546CPhase 22 trials
Astellas · Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- DKN-01LY2812176Phase 21 trial
Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer
- ImofinostatABT-301, MPT0E028Phase 21 trial
Anbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)
- TL938Phase 21 trial
Teligene US · Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.